ClinicalTrials.gg
TerminatedNCT02195817Updated Feb 28, 2017

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

A Phase 4 interventional study of Selincro® 18 mg with continuous psychosocial support: Cohort A and Initial psychosocial support: Cohort B in Alcohol Dependence, sponsored by H. Lundbeck A/S. Terminated at 48 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was terminated due to enrolment challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
378
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.

Enrollment
6th of 12
378 · median 212
Started
2014
with 1 other
Phase 4
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
5 of 12
H. Lundbeck A/S

Among the 12 studies testing nalmefene in Alcoholism, this one is the 6th largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 4, and was the 4th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About nalmefene

nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing nalmefene in Alcoholism as a file.
02

Study summary

To determine the reduction in alcohol consumption in patients with alcohol dependence treated with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in primary care

Read the detailed description

635 patients are planned (total number of patients) with 475 patients treated with Selincro® (Cohort A) and 160 patients not treated with Selincro® (Cohort B) to determine the reduction in alcohol consumption in patients with alcohol dependence.

Cohort A will comprise patients who maintain a high drinking risk level (DRL, defined by World Health Organization (WHO) as >60g alcohol/day for a man or >40g alcohol/day for a woman), or above, in the period between the Screening and Inclusion Visits.

Cohort B will comprise patients who reduce their alcohol consumption in the period between the Screening and Inclusion visits, that is, patients who do not maintain at least a high DRL at the Inclusion Visit (and are therefore not eligible for treatment with nalmefene according to the SmPC).

03

Conditions studied

  • Alcohol Dependence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

To ensure the study is broadly representative of primary care clinical practice, minimal inclusion and exclusion criteria are imposed with the main exclusion criteria relating to to the prescription of Selincro® and reflecting the indication wording in the SmPC.

Inclusion criteria

Inclusion Criteria:

  • The patient has alcohol dependence diagnosed according to ICD-10.
  • The patient has had a high DRL in the 4 weeks preceding the Screening Visit.
  • The patient is a man or woman, aged ≥18 years.
  • The patient provides a stable address and telephone number.

Exclusion criteria

Exclusion Criteria:

  • The patient has one or more to the prescription of Selincro®:

    • to the active substance or to any of the
    • taking opioid analgesics
    • current or recent opioid addiction
    • acute symptoms of opioid withdrawal
    • recent use of opioids suspected
    • severe hepatic impairment ( classification)
    • severe renal impairment ( \<30 ml/min per 1.73 m2)
    • a recent history of acute alcohol withdrawal syndrome (including hallucinations, seizures, or delirium tremens)
  • The patient has had \<6 HDDs (defined by the European Medicines Agency as a day with an alcohol consumption >60g for men or >40g for women) in the 4 weeks preceding the Screening Visit.
  • The patient has physical alcohol withdrawal symptoms and requires immediate detoxification for which inpatient treatment is required.
  • The patient is currently participating or has recently (in the 4 weeks preceding the Screening Visit) participated in a treatment or support programme for alcohol-use disorders, including Alcohol Anonymous, detoxification treatment, and treatment of alcohol withdrawal symptoms, or the patient is already taking nalmefene or has taken nalmefene in the 6 months preceding the Screening Visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
378 participants (actual)

Study arms

  • Other
    Selincro® 18 mg with continuous psychosocial support: Cohort A

    Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support

    Drug: Selincro® 18 mg with continuous psychosocial support: Cohort A

  • Other
    Initial psychosocial support: Cohort B

    Initial psychosocial support followed by usual care practice, 12-week Observational Period

    Other: Initial psychosocial support: Cohort B

Interventions

  • DrugSelincro® 18 mg with continuous psychosocial support: Cohort A

    Drug page: Nalmefene

    Also known as: nalmefene

  • OtherInitial psychosocial support: Cohort B
06

What researchers measure

Primary outcomes

  1. Change in the number of Heavy Drinking Days (HDDs) (days/month)

    Cohort A

    Time frame: Baseline to Month 3

Secondary outcomes

  1. Change in Total Alcohol Consumption (TAC) (g/day)

    Cohort A

    Time frame: Baseline to Month 3

  2. Drinking Risk Level response (RSDRL); defined as a downward shift in Drinking Risk Level (DRL); for patients with a very high DRL at baseline, a shift to medium DRL or below; for patients with a high DRL at baseline, a shift to low DRL or below

    Cohort A

    Time frame: Baseline to Month 3

  3. RLDRL response; defined as a downward shift in DRL to low DRL or below

    Cohort A

    Time frame: Baseline to Month 3

  4. Response defined as ≥70% reduction in TAC

    Cohort A

    Time frame: Baseline to Month 3

  5. Response defined as 0 to 4 HDDs (days/month)

    Cohort A

    Time frame: Month 3

  6. Change in Clinical Global Impression - Severity of Illness (CGI-S) score

    Cohort A

    Time frame: Baseline to Week 12

  7. Clinical Global Impression - Global Improvement (CGI-I)

    Cohort A

    Time frame: Week 12

  8. y-glutamyl transferase (y-GT)

    Cohort A

    Time frame: Week 12

  9. Alanine aminotransferase (ALT)

    Cohort A

    Time frame: Week 12

  10. Aspartate aminotransferase (AST)

    Cohort A

    Time frame: Week 12

  11. Change in 36-item Short-form Health Survey version 2 (SF-36) (only for patients in France and the United Kingdom)

    Cohort A

    Time frame: Baseline to Week 12

07

Study locations

48 sites
  • FR010
    Becon-les-Granits, France
  • FR001
    Bordeaux, France
  • FR005
    Bordeaux, France
  • FR009
    Cestas, France
  • FR012
    Chauny, France
  • FR002
    Coulounieix-Chamiers, France
  • FR008
    La Teste De Buch, France
  • FR007
    Mont de Marsan, France
  • FR011
    Narbonne, France
  • FR003
    Targon, France
  • FR006
    Tonneins, France
  • FR004
    Vieux Boucau, France
  • DE002
    Berlin, Germany
  • DE005
    Berlin, Germany
  • DE006
    Essen, Germany
  • DE003
    Jahnsdorf, Germany
  • DE004
    Jahnsdorf, Germany
  • DE011
    Mannheim, Germany
  • DE009
    Nurnberg, Germany
  • DE010
    Offenbach, Germany
  • DE001
    Wallerfing, Germany
  • DE007
    Weilburg, Germany
  • DE008
    Weinheim, Germany
  • ES001
    Badalona, Spain
  • ES010
    Badalona, Spain
  • ES003
    Barcelona, Spain
  • ES004
    Barcelona, Spain
  • ES008
    Canet de Mar, Spain
  • ES007
    El Prat de Llobregat, Spain
  • ES006
    Hospitalet del Llobregat, Spain
  • ES009
    Hospitalet del Llobregat, Spain
  • ES011
    Hospitalet del Llobregat, Spain
  • ES002
    Mataro, Spain
  • ES013
    Matar, Spain
  • ES012
    Sabadell, Spain
  • ES005
    Tarragona, Spain
  • GB011
    Ballymena, United Kingdom
  • GB008
    Belfast, United Kingdom
  • GB009
    Belfast, United Kingdom
  • GB004
    Cardiff, United Kingdom
  • GB005
    Cardiff, United Kingdom
  • GB001
    Coatbridge, United Kingdom
  • GB002
    Glasgow, United Kingdom
  • GB003
    Lanarkshire, United Kingdom
  • GB006
    Swansea, United Kingdom
  • GB007
    Swansea, United Kingdom
  • GB010
    Swansea, United Kingdom
  • GB106
    Swansea, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Feb 2016, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2014
First posted
Jul 21, 2014
StartActual
Aug 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02195817
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Aug 2014
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Feb 28, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion